EU GMP Annex 1 Revisions Will Require Stronger Visual Inspection Programs
Executive Summary
An industry expert tells pharmaceutical manufacturers to be aware of changes proposed for Annex 1 of the European Commission's GMP guide that affect visual inspections and particulate control for new parenteral drugs. The revision calls for stricter standards for visually screening products for defects.